Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Novo Nordisk

253.00 DKK0.00 %25.9, 17.04
1,077 following

NOVO B

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
0.00 %
-15.46 %
-18.79 %
+6.30 %
-22.21 %
-31.91 %
-60.56 %
-21.17 %
+20,221.29 %

Novo Nordisk is a producer of insulin for diabetes treatment. In addition to the specialist expertise in diabetes, the company produces drugs for hormone treatment as well as for hemophilia and bleeding disorders. The products are found on a global market and are sold under separate brands. Novo Nordisk was founded in 1923 and is headquartered in Bagsværd, Denmark.

Read more
Market cap
1.13T DKK
Turnover
988.93M DKK
Revenue
309.06B
EBIT %
41.3 %
P/E
10.97
Dividend yield-%
4.62 %
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
ShowingAll content types

Forum discussions
Novo has launched its new Awiqli insulin in the United States for type 2 diabetes. Its greatest advantage is that the insulin only needs to be injected once a week instead of the current daily injection. According to studies, it worked just as well in blood sugar management as daily...
8/11/2026, 1:51 PM
by Sijoittaja-alokas
34
This post is so negative that it made me take a look at the author’s previous posts. The writing seems to be in line with posts from several years ago, which explains why the author interprets even positive drivers as negative forecasts in the text. Criticism is always a good thing...
8/6/2026, 6:38 AM
by Kari Kokkonen
19
China’s drug regulator has accepted the marketing authorization application for Novo’s oral weight-loss drug Wegovy. The company is eager to compete in the rapidly growing market, particularly against Eli Lilly. Novo Nordisk said on Thursday that China’s drug regulator accepted its...
8/27/2026, 2:43 PM
by Sijoittaja-alokas
16
Picked up a recent CNBC interview from Nordnet where CEO Mike Doustdar breaks down the current situation and the optimistic outlook in plain language.
8/7/2026, 2:46 PM
by Keepitcoming
13
Novo’s CMD in London. The market side isn’t very convinced (-5%). The press release on the main points of the CMD was at least quite high-level jargon. Key highlights of the strategic ambitions for 20301 are: Grow and diversify pipeline Launch >5 multi-blockbusters by 2030 and deliver...
9/21/2026, 9:16 AM
by Cotr
10
Inderes Novo Nordisk enters next chapter to bring better health to more people,... Bagsværd, Denmark, 14 September 2026 – Novo Nordisk marked the beginning of its next chapter today by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single ‘Novo’ name, ... Corporate...
9/14/2026, 7:19 AM
by Gwertheney
10
And the German market seems to have opened today, sales are certainly massive and profits handsome, but still, there should be a couple more pillars to support this business. GLP-1 pills are not quite enough for a new rise for Novo. https://www.reuters.com/legal/litigation/novo-nordisk...
9/1/2026, 9:55 AM
by Keepitcoming
8
Read more on our forum
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
4.11
2026

Interim report Q3'26

HCA Morgenbørs 25/09 - Interview med Christian Stig Møller fra Nordic Bloom og rygter om aftale mellem Iran/USA
Video25.09.2026, 09.36 by
Michael Friis, Victor Skriver

HCA Morgenbørs 25/09 - Interview med Christian Stig Møller fra Nordic Bloom og rygter om aftale mellem Iran/USA

Udsigt til en positiv dag i Europa på rygter om aftale mellem Iran/USA. Fokus på Novo, Novonesis. Gæst i studiet her til morgen er Christian Stig Møller fra Nordic Bloom for at se nærmere på den næste tids US IPO's.

Novo NordiskNovonesisA.P. Møller - MærskTormPandoraVestas Wind SystemsØrsted
Press release22.09.2026, 14.00

Novo and UNICEF expand partnership to support a healthier start for more than 80 million children

Novo Nordisk
HCA Morgenbørs 22/09 – Interview med Thomas Black fra FBV og flad åbning i Europa
Video22.09.2026, 09.45 by
Michael Friis, Jacob Frehr

HCA Morgenbørs 22/09 – Interview med Thomas Black fra FBV og flad åbning i Europa

Europa ser ud til at åbne fladt op, og kan dermed ikke følge trop på de store stigninger i AI sektoren inspireret af en Muse. Herhjemme vil der blandt andet være fokus på Novo, Zealand, DSV Gæst i studiet her til morgen er Thomas Black fra FBV.

Novo NordiskDSVCadelerNordnetMetaØrstedTormZealand Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release21.09.2026, 14.37

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release21.09.2026, 12.24

Novo's CagriSema delivers superior weight loss versus tirzepatide in REIMAGINE 5 trial

Novo Nordisk
HCA Morgenbørs 21/09 – Lars Hytting interview med fokus på Novo
Video21.09.2026, 10.01 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 21/09 – Lars Hytting interview med fokus på Novo

Lavere oliepriser, positive toner forud for Kina/USA topmøde løfter aktier fra morgenstunden. Herhjemme vil der blandt andet være fokus på Novo, Lundbeck. Gæst i studiet her til morgen er Lars Hytting fra Arthascope, hvor vi kigger nærmere på Novo.

Novo NordiskA.P. Møller - MærskGN Store NordGrønlandsbankenAlm. BrandNKTTormPandora
Press release21.09.2026, 10.00

Highlights to be presented at Novo’s Capital Markets Day 2026

Novo Nordisk
Press release18.09.2026, 12.36

Novo’s once-weekly Sogroya® (somapacitan) receives positive CHMP opinion in Europe for children with idiopathic short stature (unexplained shortness)

Novo Nordisk
Regulatory press release17.09.2026, 16.14

Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A

Novo Nordisk
Press release16.09.2026, 14.00

Novo and Anthropic will collaborate to advance drug discovery with Claude

Novo Nordisk
Press release16.09.2026, 09.00

Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026

Novo Nordisk
Regulatory press release14.09.2026, 15.13

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
HCA Morgenbørs 14/09 - Impero CEO-Interview og markederne presses af AI og olie
Video14.09.2026, 09.35 by
Michael Friis, Rasmus Køjborg

HCA Morgenbørs 14/09 - Impero CEO-Interview og markederne presses af AI og olie

Europæiske futures indikerer en negativ åbning, markeder presses af AI og olie. Herhjemme vil der blandt andet være fokus på ISS, FLS og Carlsberg. Gæst i studiet her til morgen er CEO Rikke Skov fra Impero.

ISSFLSmidth & Co.ImperoCarlsbergNovo NordiskA.P. Møller - MærskNetcompany GroupTrifork GroupNKTVestas Wind SystemsØrsted
Press release14.09.2026, 09.05

Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture

Novo Nordisk
HCA Morgenbørs 11/09 - Movinn CEO-Interview og fokus på eftermiddagens inflationstal
Video11.09.2026, 09.20 by
Victor Skriver, Jacob Frehr

HCA Morgenbørs 11/09 - Movinn CEO-Interview og fokus på eftermiddagens inflationstal

Europæiske futures indikerer en positiv åbning på en dag, hvor fokus er rettet mod eftermiddagens amerikanske inflationstal. Herhjemme vil der blandt andet være fokus på ChemoMetec, Novonesis, ISS, Ørsted og Novo Nordisk. Gæst i studiet her til morgen er CEO, Patrick Block fra Movinn.

ØrstedChemoMetecISSNovo NordiskNovonesisA.P. Møller - Mærsk
HCA Morgenbørs 10/09 - Fokus på fredagens afgørende inflationsrapport
Video10.09.2026, 10.55 by
Michael Friis, Nikolaj Pedersen

HCA Morgenbørs 10/09 - Fokus på fredagens afgørende inflationsrapport

Europæiske futures indikerer en begrænset positiv åbning efter gårsdagens nedtur, forud for fredagens afgørende inflationsrapport. Herhjemme fokus på blandt andet Mærsk, Novo, NTG, B&O.

Bang & OlufsenLundbeckNovo NordiskDSVA.P. Møller - MærskNTG Nordic Transport Group
HCA Morgenbørs 08/09 - Napatech i fokus i interview med Anders Knudsen og stigende oliepriser
Video08.09.2026, 09.48 by
Jacob Frehr, Michael Friis

HCA Morgenbørs 08/09 - Napatech i fokus i interview med Anders Knudsen og stigende oliepriser

Udsigt til faldende aktiemarkeder fra morgenstunden i Europa på stigende oliepriser. Gæst i studiet her til morgen er Anders Knudsen, hvor vi sætter fokus på casen i Napatech.

NapatechZealand PharmaLundbeckNetcompany GroupGenmabISSNovo NordiskTorm
Regulatory press release07.09.2026, 13.12

Novo Nordisk A/S - share repurchase programme

Novo Nordisk
Press release07.09.2026, 12.00

Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification

Novo Nordisk
HCA Morgenbørs 02/09 - Novo Nordisk vs. Eli Lilly med Claus Johansen og dagens aktiemarked
Video02.09.2026, 09.31 by
Jacob Frehr, Victor Skriver

HCA Morgenbørs 02/09 - Novo Nordisk vs. Eli Lilly med Claus Johansen og dagens aktiemarked

Negative futures fra morgenstunden, hvor den eskalerede konflikt mellem USA og Iran fortsætter med at tynge stemningen. Herhjemme fokus på analytikerændringer og nyheder. Gæst i studiet her til morgen er Claus Johansen fra Global Health Invest.

Novo NordiskSchouw & CoMatasFreetrailer GroupNovonesisVestas Wind Systems